ProQR Therapeutics BV share price logo

ProQR Therapeutics BV Share Price

NASDAQ: PRQR

Small Cap

$2.00

+0.05

(+2.82%)

as on

ProQR Therapeutics BV Stock Performance

as on April 18, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $1.96
    $2.06
    downward going graph

    2.00%

    Downside

    3.00%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.12
    $3.10
    downward going graph

    44.00%

    Downside

    55.00%

    Upside

    downward going graph

ProQR Therapeutics BV share price movements today

Previous Close
$1.95
Open
$2.01
Volume
1.1M
Day's Low - High
$1.96 - $2.06
52 Week Low - High
$1.12 - $3.10

ProQR Therapeutics BV Historical Returns

1 Month Return
+ 15.7 %
3 Month Return
+ 20.61 %
1 Year Return
+ 74.56 %
3 Year Return
-8.29 %
5 Year Return
-66.83 %

ProQR Therapeutics BV Stock Fundamentals & Key Indicators

Check ProQR Therapeutics BV market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$205.5M

EPS (TTM)

-0.5988

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-42.5M

Revenue (TTM)

16.3M

Profit Margin

-258.05%

Return On Equity TTM

-61.17%

ProQR Therapeutics BV vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of ProQR Therapeutics BV with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
ProQR Therapeutics BV image
ProQR Therapeutics BV
BUY$205.5M-66.83%NA-258.05%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$41.3B122.97%133.478.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$110.8B101.1%28.4232.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$37.2BNA131.655.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$78.9B49.34%17.9831.41%

Stock Returns calculator for ProQR Therapeutics BV Stock including INR - Dollar returns

The ProQR Therapeutics BV stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

ProQR Therapeutics BV investment value today

Current value as on today

₹1,90,053

Returns

₹90,053

(+90.05%)

Returns from ProQR Therapeutics BV Stock

₹75,439 (+75.44%)

Dollar Impact

₹14,614 (+14.61%)

Analyst Recommendation on ProQR Therapeutics BV Stock

Based on 13 analysts

BUY

84.62%

Buy

15.38%

Hold

0.00%

Sell

Based on 13 analysts, 84.62% of analysts recommend a 'BUY' rating for ProQR Therapeutics BV. Average target price of $8.88

ProQR Therapeutics BV Share Price Target

Get share price movements and forecasts by analysts on ProQR Therapeutics BV.

What analysts predicted

77.48%UPSIDE

Target Price

$8.88

Current Price

$2

Analyzed by

13 Analysts

Target

$8.88

ProQR Therapeutics BV target price $8.88, a slight upside of 77.48% compared to current price of $2. According to 13 analysts rating.

ProQR Therapeutics BV Stock’s Investor Sentiment and Interest

Search interest for ProQR Therapeutics BV Stock has increased by 178% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:178% versus previous 30 day period

ProQR Therapeutics BV Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
1
3
4
6
4
4
4
3
2
4
Gross Profit
1
3
4
6
4
4
4
3
2
3
Operating Income
-7
-6
-8
-3
-8
-10
-10
-12
-11
-9
EBITDA
-6
0
-7
-2
-8
-5
-10
-11
-10
-8
Interest Expense
0
0
0
0
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-5
-5
-7
-2
-8
-9
-10
-12
-11
-8
Income Tax Expense
0
0
0
0
-
-
-
0
-
0
Net Income
-6
-5
-8
-2
-9
-9
-10
-12
-11
-8
Net Profit Margin
-416.79%
-166.96%
-172.09%
-42.70%
-210.98%
-216.04%
-223.04%
-319.07%
-377.56%
-190.27%

ProQR Therapeutics BV Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
2
-1
5
2
1
1
3
7
19
15
Gross Profit
1
-2
4
-127
1
1
3
7
19
12
Operating Income
-39
-40
-36
-57
-42
-57
-65
-31
-30
-42
EBITDA
-120
-40
-35
-174
-48
-54
-56
-24
-24
-39
Interest Expense
0
0
0
1
2
3
5
1
1
0
Depreciation
-
1
0
2
2
2
2
2
2
2
Income Before Tax
-39
-43
-37
-56
-46
-60
-64
-27
-27
-40
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-41
-51
-41
-63
-56
-68
-68
-30
-29
-40
Net Profit Margin
-1713.54%
2853.96%
-746.69%
-2935.64%
-4525.27%
-4549.81%
-1792.54%
-431.67%
-146.86%
-265.21%

ProQR Therapeutics BV Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-5
-7
-2
-8
-9
-10
-12
-11
-8
Operating Cash Flow
-5
-15
-6
-5
-9
-15
-11
-12
-13
Investing Cash Flow
5
-17
0
16
-2
0
0
0
0
Financing Cash Flow
-1
0
0
0
71
0
0
0
0
Change in Cash
-1
-33
-6
10
60
-16
-12
-12
-14

ProQR Therapeutics BV Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-43
-37
-56
-46
-60
-64
-27
-27
-40
Operating Cash Flow
-34
-30
-43
-47
-26
-68
21
-36
-50
Investing Cash Flow
0
0
0
0
0
0
4
-4
0
Financing Cash Flow
26
88
50
14
136
-30
-2
70
-1
Change in Cash
-11
57
6
-36
111
-92
24
30
-39

Global Institutional Holdings in ProQR Therapeutics BV

Funds
Holdings
Two Sigma Investments LLC
0.8%
Kynam Capital Management, LP
1.49%
Citadel Advisors Llc
0.62%
Millennium Management LLC
1.24%
Privium Fund Management B.V.
5.09%
See all

Insights on ProQR Therapeutics BV

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, PRQR has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 2.91M → 4.64M (in $), with an average increase of 37.2% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, PRQR stock has moved up by 25.2%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -12.17M → -8.83M (in $), with an average increase of 17.6% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 25.3% return, outperforming this stock by 36.1%

About ProQR Therapeutics BV

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
OrganisationProQR Therapeutics BV
HeadquartersZernikedreef 9, Leiden, Netherlands, 2333 CK
IndustryBiotechnology
CEOMr. Daniel Anton de Boer
E-voting on sharesClick here to vote

Key Management of ProQR Therapeutics BV

Name

Title

Ms. Sheila Sponselee

Chief People & Operations Officer

Ms. Sarah Cue Kiely

Vice President of Investor Relations & Corporate Communications

Dr. Cristina Lopez Lopez M.D., Ph.D.

Chief Medical Officer

Ms. Sandra van der Kolk

Junior Financial Controller

Mr. Daniel Anton de Boer

Founder, CEO & Executive Director

Dr. Gerard Platenburg Ph.D.

Co-Founder, Chief Scientific Officer & Executive Director

Mr. Dennis Hom

Chief Financial Officer

FAQs

What is ProQR Therapeutics BV share price today?

ProQR Therapeutics BV share price today is $2 as on at the close of the market. ProQR Therapeutics BV share today touched a day high of $2.06 and a low of $1.96.

What is the 52 week high and 52 week low for ProQR Therapeutics BV share?

ProQR Therapeutics BV share touched a 52 week high of $3.1 on and a 52 week low of $1.12 on . ProQR Therapeutics BV stock price today i.e. is closed at $2,which is 35.48% down from its 52 week high and 78.57% up from its 52 week low.

What is ProQR Therapeutics BV's market capitalisation today?

ProQR Therapeutics BV market capitalisation is $0.00T as on .

How to invest in ProQR Therapeutics BV Stock (PRQR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for ProQR Therapeutics BV on INDmoney app. Click on Buy button. You can invest as low as $1.5 in ProQR Therapeutics BV Shares that will get you 0.7500 shares as per ProQR Therapeutics BV share price of $2 per share as on April 18, 2026 at 1:29 am IST.

What is the minimum amount required to buy ProQR Therapeutics BV Stock (PRQR) from India?

Indian investors can start investing in ProQR Therapeutics BV (PRQR) shares with as little as ₹92.575 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹925.75 in ProQR Therapeutics BV stock (as per the Rupee-Dollar exchange rate as on ). Based on ProQR Therapeutics BV share’s latest price of $2 as on April 18, 2026 at 1:29 am IST, you will get 5.0000 shares of ProQR Therapeutics BV. Learn more about fractional shares .

What are the returns that ProQR Therapeutics BV has given to Indian investors in the last 5 years?

ProQR Therapeutics BV stock has given -66.83% share price returns and 24.75% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?